Glyscend Therapeutics Completes $20.5M Financing Round to Advance Novel Oral Polymer Therapy for Type 2 Diabetes –Patient-Friendly Therapy Designed to Mimic the Dramatic Metabolic Benefits of Bariatric Surgery ––Company Aims to Begin First-in-Human Trials in Australia Next Year –Karen Talmadge, PhD, Industry...